Homburger advised Novartis AG on its USD 12 bn acquisition of Avidity Biosciences, Inc.

On March 2, 2026, Novartis AG (SIX: NOVN / NYSE: NVS), acting through one of its wholly-owned indirect subsidiaries, completed the acquisition of Avidity Biosciences, Inc. (NASDAQ: RNAM), pursuant to the terms of the merger agreement for a total value of approximately USD 12 bn.

Homburger advised Novartis AG and its subsidiaries with respect to all Swiss law aspects of the acquisition of Avidity Biosciences, Inc.

The Homburger team was led by Frank Gerhard (Corporate / M&A) and Benjamin Leisinger (Capital Markets) and included Stefan Bindschedler (Financing), Olivier Baum (Capital Markets, Corporate / M&A) as well as Timo Hasler (Corporate / M&A).